Tonix Pharmaceuticals Holding (TNXP) Cash from Financing Activities (2010 - 2026)
Tonix Pharmaceuticals Holding (TNXP) posted quarterly Cash from Financing Activities of $20.2 million for Q1 2026, down 59.21% year-over-year from $49.5 million in Q1 2025, and down 65.84% quarter-over-quarter from $59.1 million in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $20.2 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 59.21% year-over-year to $20.2 million; the TTM figure through Mar 2026 stood at $185.2 million (changed 0.32% YoY), while the FY2025 annual figure was $214.5 million, up 59.06% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $20.2 million, down from $59.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $94.9 million in Q3 2025, with the low at -$11.5 million in Q1 2023.
- The 5-year median for Cash from Financing Activities is $13.1 million (2022), against an average of $29.1 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities plunged 188.03% in 2023, then soared 23464.62% in 2025.
- Tonix Pharmaceuticals Holding's Cash from Financing Activities stood at $7.2 million in 2022, then jumped by 463.2% to $40.7 million in 2023, then soared by 109.15% to $85.2 million in 2024, then tumbled by 30.55% to $59.1 million in 2025, then slumped by 65.84% to $20.2 million in 2026.
- Business Quant data shows TNXP's Cash from Financing Activities at $20.2 million in Q1 2026, $59.1 million in Q4 2025, and $94.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Tonix Pharmaceuticals Holding | 213.43 Mn | 213.43 Mn | 12.84 Mn | 33.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.51 Mn |
| Jun 30, 2026 | 33.51 Mn |
| Mar 31, 2026 | 20.21 Mn |
| Mar 31, 2026 | 20.21 Mn |
| Dec 31, 2025 | 59.14 Mn |
| Dec 31, 2025 | 59.14 Mn |
| Sep 30, 2025 | 94.86 Mn |
| Sep 30, 2025 | 94.86 Mn |
| Jun 30, 2025 | 10.99 Mn |
| Jun 30, 2025 | 10.99 Mn |
| Mar 31, 2025 | 49.53 Mn |
| Mar 31, 2025 | 49.53 Mn |
| Dec 31, 2024 | 85.15 Mn |
| Dec 31, 2024 | 85.15 Mn |
| Sep 30, 2024 | 42.91 Mn |
| Sep 30, 2024 | 42.91 Mn |
| Jun 30, 2024 | 7.03 Mn |
| Jun 30, 2024 | 7.03 Mn |
| Mar 31, 2024 | -212,000.00 |
| Mar 31, 2024 | -212,000.00 |